Time point | DAIBD | Clinical response, n (%)* | CRP |
---|---|---|---|
Baseline | 109.3 ± 32.5 (N = 48) | 3.91 ± 4.93 (N = 44) | |
Week 4 | 50.3 ± 39.1 (N = 33)** | 27 (81.8) | 2.20 ± 4.02 (N = 38)** |
Week 8 | 39.3 ± 36.1 (N = 40)** | 35 (87.5) | 1.41 ± 3.33 (N = 39)** |
Week 12 | 47.6 ± 43.7 (N = 33)** | 30 (90.9) | 1.26 ± 2.03 (N = 43)** |
Week 28 | 35.8 ± 37.1 (N = 30)** | 27 (90.0) | 1.08 ± 2.18 (N = 40)** |
Week 56 | 33.5 ± 29.3 (N = 29)** | 26 (89.7) | 1.20 ± 2.46 (N = 40)** |
Early termination | 110.0 ± 21.2 (N = 2) | 0 (0.0) | 4.25 ± 2.94 (N = 4) |
Serial changes in patients who were previously treated with infliximab | |||
Baseline | 104.0 ± 40.9 (N = 10) | 3.48 ± 2.58 (N = 8) | |
Week 4 | 40.6 ± 29.6 (N = 8)** | 6 (75) | 1.43 ± 1.97 (N = 10) |
Week 8 | 32.0 ± 30.9 (N = 10)** | 9 (90) | 0.36 ± 0.43 (N = 8)** |
Week 12 | 49.3 ± 62.5 (N = 9)** | 6 (66.7) | 1.50 ± 2.44 (N = 10) |
Week 28 | 23.3 ± 32.4 (N = 9)** | 8 (88.9) | 0.51 ± 0.63 (N = 9)** |
Week 56 | 20.0 ± 23.5 (N = 9)** | 8 (88.9) | 0.63 ± 0.60 (N = 10)** |